Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ: 323990)
South Korea
· Delayed Price · Currency is KRW
13,940
-140 (-0.99%)
Sep 10, 2024, 9:00 AM KST
Vaxcell-Bio Therapeutics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 9, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 310,638 | 516,197 | 519,865 | 660,678 | 2,517,196 | - | |
Market Cap Growth | -36.16% | -0.71% | -21.31% | -73.75% | - | - | |
Enterprise Value | 263,792 | 504,030 | 497,951 | 646,323 | 2,482,604 | - | |
Last Close Price | 13510.00 | 22450.00 | 26694.20 | 33924.69 | 130774.23 | - | |
PE Ratio | - | -42.86 | -74.56 | -107.70 | -223.55 | - | |
PS Ratio | 4558.07 | 37614.61 | - | - | - | - | |
PB Ratio | 3.96 | 6.18 | 22.29 | 21.96 | 72.61 | - | |
P/FCF Ratio | -28.50 | -53.83 | -83.69 | -97.37 | -755.93 | - | |
P/OCF Ratio | -32.46 | -54.78 | -86.00 | -141.72 | -762.09 | - | |
EV/Sales Ratio | 4288.08 | 36727.98 | - | - | - | - | |
EV/EBITDA Ratio | -23.76 | -45.38 | -63.02 | -114.46 | -610.04 | - | |
EV/EBIT Ratio | -22.28 | -43.80 | -60.63 | -109.47 | -583.47 | - | |
EV/FCF Ratio | -21.95 | -52.56 | -80.16 | -95.25 | -745.54 | - | |
Debt / Equity Ratio | 0.04 | 0.00 | 0.00 | 0.01 | 0.01 | 0.05 | |
Debt / FCF Ratio | -0.23 | -0.04 | -0.02 | -0.03 | -0.10 | -0.11 | |
Asset Turnover | 0.00 | 0.00 | - | - | - | - | |
Quick Ratio | 22.16 | 54.78 | 67.10 | 70.51 | 31.98 | 19.19 | |
Current Ratio | 22.43 | 55.43 | 68.06 | 71.88 | 32.29 | 19.54 | |
Return on Equity (ROE) | -21.52% | -19.24% | -25.56% | -14.71% | -18.22% | -987.03% | |
Return on Assets (ROA) | -16.22% | -13.18% | -18.52% | -11.05% | -11.68% | -22.49% | |
Return on Capital (ROIC) | -16.73% | -13.41% | -19.11% | -11.30% | -11.94% | -52.09% | |
Earnings Yield | -3.29% | -1.99% | -1.31% | -0.72% | -0.16% | - | |
FCF Yield | -3.87% | -1.86% | -1.19% | -1.03% | -0.13% | - | |
Buyback Yield / Dilution | -23.09% | -2.89% | -26.09% | -122.02% | -55.35% | -23.67% | |
Total Shareholder Return | -23.09% | -2.89% | -26.09% | -122.02% | -55.35% | -23.67% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.